Sharon N. Teraoka, Ph.D. and Kathleen E. Malone, Ph.D. contributed equally to this article.
Original Article
Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history
Article first published online: 9 AUG 2001
DOI: 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G
Copyright © 2001 American Cancer Society
Additional Information
How to Cite
Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R. and Concannon, P. (2001), Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer, 92: 479–487. doi: 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G
Publication History
- Issue published online: 9 AUG 2001
- Article first published online: 9 AUG 2001
- Manuscript Revised: 19 APR 2001
- Manuscript Received: 20 DEC 2000
- Abstract
- Article
- References
- Cited By
Keywords:
- breast carcinoma;
- ataxia-telangiectasia;
- missense mutations;
- DNA double-strand break repair
Mutations in the ATM gene, specifically those predicted to result in amino acid substitutions, were significantly increased in breast carcinoma cases selected for positive family history.
Abstract
BACKGROUND
An increased incidence of breast carcinoma has been reported among relatives of individuals who are affected with the rare recessive disorder, ataxia-telangiectasia (A-T), and who are heterozygous for mutations in the ataxia-telangiectasia mutated (ATM) gene. However, most studies of breast carcinoma cases from the general population have failed to find a higher incidence of ATM mutations in cases when compared with controls.
METHODS
Genomic DNA samples from 258 individuals were screened for mutations of all types in each of the 62 coding exons of the ATM gene; 142 of these were from breast carcinoma cases with a first-degree family history or early age at diagnosis, 35 were from cases selected for the presence of either known disease-related mutations (n = 25) or missense alterations of unknown consequences (n = 10) in BRCA1 or BRCA2, and 81 were from matched controls.
RESULTS
A total of 12 individuals with ATM mutations were identified, 11 among 142 breast carcinoma cases (7.7%; 95% CI, 3.9–13.4%) and 1 among 81 controls (1.2%; 95% CI, 0.0–6.7%) (P = 0.06). All mutations detected were of the missense type; none were predicted to truncate the ATM protein. Among cases, mutations were found exclusively in patients with a family history of breast carcinoma (12.1%; 95% CI, 6.2–20.6%) (P = 0.02). Similar frequencies of ATM mutations were found in 35 additional cases selected for the presence of BRCA1 or BRCA2 mutations when compared with cases overall.
CONCLUSIONS
ATM mutations, specifically missense mutations, are more common in breast carcinoma cases selected for first-degree family history and early age at diagnosis. Cancer 2001;92:479–87. © 2001 American Cancer Society.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)